Impact Factor
3.36
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.83
480 total citations
h5-index
27
h5 depth signal
Cited share
72.6%
130 of 179
Total citations
480
Citation footprint
Metric signal
2.88
External metric anchor
Self-citation
2.9%
14 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
187
France
157
Belgium
130
Italy
120
United Kingdom
52
Citing Fields of Research
Oncology
273
Immunology
160
Lung Cancer
100
Breast Cancer
85
Lymphomas
81
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,822
Articles tracked across the journal lifetime
Indexed publication set
179
130 cited publications
Last 12 months
73
6.1 publications/month
Open access share
8.2%
6 OA publications in the last year
Leading citing country
United States
187 citing publications
Leading citing field
Oncology
273 citing publications
Latest tracked publication
8 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1989-
v1n1, 1989-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Immunology
Lymphomas
Lung Cancer
Palliative Care
Musculoskeletal & Nerve Cancer
Broad Categories
Neoplasms
Immunology
Lymphomas
Musculoskeletal & Nerve Cancer
Lung Cancer
Reproductive Health
Palliative Care
Brain Imaging
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/cco.0000000000001280
Open DOI
Editorial introductions
02
DOI 10.1097/cco.0000000000001272
Open DOI
Electronic patient-reported outcomes platforms to shift from episodic to continuous oncology in breast cancer
Purpose of review: To critically examine the clinical value of patient-reported outcomes (PROs) assessed through electronic tools (ePROs) in breast cancer, with a focus on their impact on patient management and real-world implementation....
03
DOI 10.1097/cco.0000000000001270
Open DOI
Time-of-day administration of immune checkpoint inhibitors: current clinical evidence and future directions for breast cancer
Purpose of review: Immune checkpoint inhibitors (ICIs) are increasingly used in breast cancer, particularly in triple-negative breast cancer. This review summarizes the biologic rationale and emerging clinical evidence for time-of-day IC...
04
DOI 10.1097/cco.0000000000001274
Open DOI
Adjuvant treatments for stage I breast cancers of one centimeter or less
Purpose of review: The increasing detection of subcentimetric breast cancers (BC) through widespread implementation of mammographic screening has raised important questions regarding the optimal management of patients with stage I tumors...
05
DOI 10.1097/cco.0000000000001277
Open DOI
Precision medicine for pediatric gliomas
Purpose of review: The fifth edition of the WHO Classification of Tumors of the Central Nervous System marked a paradigm shift from predominantly histopathological classification toward integrated molecular-pathological definitions. This...
06
DOI 10.1097/cco.0000000000001275
Open DOI
Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers
Purpose of review: Germline or somatic biallelic inactivation of BRCA1 , BRCA2 and PALB2 genes define a clinically and biologically distinct subset of breast cancers characterized by homologous recombination deficiency (HRD) and sensitiv...
07
DOI 10.1097/cco.0000000000001279
Open DOI
Emerging role of targeted therapy in drug-resistant epilepsy in patients with glioma
Purpose of review: Seizures are among the most frequent and disabling manifestations of gliomas, and in some patients remain drug-resistant despite optimal antiseizure medication and standard antitumour treatments. This review examines t...
08
DOI 10.1097/cco.0000000000001278
Open DOI
The evolving role of nuclear medicine in differentiating pseudoprogression from tumor progression in gliomas
Purpose of review: Gliomas remain associated with poor outcomes, despite multimodal treatment. Response assessment relies primarily on MRI; however, treatment-related changes (TRC), particularly pseudoprogression (psPD), may mimic tumor ...
09
DOI 10.1097/cco.0000000000001269
Open DOI
Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma
Purpose of review: Improved survival in primary CNS lymphoma (PCNSL) has increased the importance of delayed treatment-related neurotoxicity as a determinant of functional outcome and quality of life. This review summarizes contemporary ...
10
DOI 10.1097/cco.0000000000001276
Open DOI
Safety management of anti TROP2 ADCs in patients with breast cancer
Purpose of review: TROP2-directed antibody–drug conjugates (trophoblast antigen 2-directed ADCs) are becoming increasingly integrated into breast cancer treatment across multiple disease settings. Their expanding use makes a detailed und...
Bibliographical & Catalog Notes
Includes a section called: Bibliography of the current world literature.
Vol. 1 complete in 2 issues.
Also issued online.
Vol. 1, no. 1 (OCTOBER 1989)19900912 Notice published Printed on acid-free paper